As regulators push to phase out animal testing, Charles River’s Steve Bulera notes that widespread implementation of ...

Alpha1H shows benefit in non-muscle invasive bladder cancer, shrinking tumors and boosting the immune system with manageable ...

Akeso enrolls first patient in pivotal phase III trial of cadonilimab for perioperative treatment of resectable gastric cancer: Hong Kong Friday, August 22, 2025, 18:00 Hrs [IST] ...

Tryptamine Therapeutics has struck an exclusive deal with world-leading psychedelic researchers Professor Robin ...

UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

Strategic leadership appointment strengthens company’s commercial approach to drive continued growth and deliver long-term value ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

Correa and Bergman are co-chairs of the congressional Psychedelics Advancing Therapies (PATH) Caucus. Mercer is a Marine Corps veteran and the executive director of Healing Breakthrough.

Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...

An overview of how recent funding reductions are reshaping clinical trial operations, from site sustainability and patient ...

With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing ...